Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: An open-label, extension study

Shinya Katsutani, Yoshiaki Tomiyama, Akiro Kimura, Yoshitaka Miyakawa, Shinichiro Okamoto, Yasushi Okoshi, Haruhiko Ninomiya, Hiroshi Kosugi, Kazuyoshi Ishii, Yasuo Ikeda, Toshihiro Hattori, Koichi Katsura, Yuzuru Kanakura

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: An open-label, extension study'. Together they form a unique fingerprint.

Medicine & Life Sciences